Owen Alice J, Reid Christopher M
Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Integr Blood Press Control. 2012;5:1-7. doi: 10.2147/IBPC.S9335. Epub 2012 Jan 6.
Amlodipine is a long-acting, dihydropyridine calcium antagonist now widely used for lowering of elevated blood pressure. In recent years it has been shown to be effective in reducing both blood pressure and risk of cardiovascular (CV) events when used in combination with other antihypertensive agents of different classes. Strong evidence of cardiovascular benefit has been attained for combination of amlodipine with diuretics or angiotensin converting enzyme (ACE) inhibitors in a number of high-risk CV groups, including those with established coronary artery disease, diabetes, and at risk of renal disease. Combination therapies of amlodipine with other agents eliciting renin-angiotensin-aldosterone system blockade (angiotensin II receptor blockers or renin inhibitors) have been shown to be effective blood pressure-lowering strategies, but await the results of ongoing trials for direct evidence of benefit for renal disease progression and CV morbidity and mortality.
氨氯地平是一种长效二氢吡啶类钙拮抗剂,目前广泛用于降低血压升高。近年来,当与其他不同类别的抗高血压药物联合使用时,已证明它在降低血压和心血管(CV)事件风险方面均有效。在许多高危CV组中,包括那些已确诊冠心病、糖尿病和有肾病风险的患者,氨氯地平与利尿剂或血管紧张素转换酶(ACE)抑制剂联合使用已获得心血管益处的有力证据。氨氯地平与其他引起肾素-血管紧张素-醛固酮系统阻滞的药物(血管紧张素II受体阻滞剂或肾素抑制剂)联合治疗已被证明是有效的降压策略,但仍需等待正在进行的试验结果,以获得关于肾病进展以及CV发病率和死亡率益处的直接证据。